Axonics (AXNX) said Thursday that Australia's Therapeutic Goods Administration has approved the marketing of the company's R20 rechargeable sacral neuromodulation system as a treatment for adults suffering from overactive bladder and fecal incontinence.
The company said it expects to start sales of the R20 in Australia in November.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.